AGT and diabetes mellitus: Pharmacological inhibition, coupled with the studies in experimental diabetes, suggests that (1) there is a shift in the profile of angiotensin peptides in diabetes, with Ang II the primary peptide, and (2) with treatment, there is a reversal, with Ang-(1-7) becoming the predominant peptide.